Gastrointestinale Stromatumoren

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: OA Dr. Ferdinand Ploner

Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz


Referenzen:

– ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 07): vii49–vii55.

– Bareck E, Ba-Ssalamah A, Brodowicz T et al., Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria. Wien Med Wochenschr 2013; 163:137–152.

– Demetri G, Benjamin R, Blanke C et al., NCCN Task Force Report: Optimal Management of Patients with Gastrointestinal Stromal Tumor (GIST) – Update of the NCCN Clinical Practice Guidelines J Nat Comp Canc Netw 2007; 5(Suppl 2): S1-29.

– Joensuu H, Eriksson M, Sundby Hall K et al., One vs. three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307:1265–1272.

– Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28:1247–1253.

– Demetri GD, van Oosterom AT, Garrett CR et al., Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329–1338.

– Demetri GD, Reichardt P, Kang YK et al., Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:295–302.


SO 03|2014

Herausgeber: Univ.-Prof. Dr. Christoph Zielinski, Univ.-Prof. Dr. Markus Raderer
Publikationsdatum: 2014-11-07